The art and science of switching antipsychotic medications, part 2.
In the presentation "Switching and Metabolic Syndrome," Weiden summarizes reasons to switch antipsychotics, highlighting weight gain and other metabolic adverse events as recent treatment targets. In "Texas Medication Algorithm Project (TMAP)," Miller reviews the TMAP study design, discusses results related to the algorithm versus treatment as usual, and concludes with the implications of the study. Lambert's presentation, "Dosing and Titration Strategies to Optimize Patient Outcome When Switching Antipsychotic Therapy," reviews the decision-making process when switching patients' medication, addresses dosing and titration strategies to effectively transition between medications, and examines other factors to consider when switching pharmacotherapy.
Weiden
Peter J
PJ
Department of Psychiatry, Schizophrenia Research Program, State University of New York Downstate Medical Center and Kings County Hospital Center, Brooklyn, USA.
Miller
Alexander L
AL
Lambert
Tim J
TJ
Buckley
Peter F
PF
D000465:Algorithms; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D003657:Decision Making; D006801:Humans; D024821:Metabolic Syndrome / Q000139:chemically induced*; D011618:Psychotic Disorders / Q000188:drug therapy
D014150:Antipsychotic Agents